At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
Cobimetinibdrug
Likely dose
Cobimetinib 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Single-Dose, Randomized, Cross-Over, Relative Bioavailability, and Food Effect Study of GDC-0973 in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating Cobimetinib for Healthy Volunteers. Completed, enrolled 20 participants.
Detailed Summary
This study will be an open-label, randomized, 3-way, 6-sequence crossover study in healthy participants for determining the relative bioavailability of the tablet formulation to the capsule formulation and the effect of food on the relative bioavailability of the tablet formulation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2010
Enrollment StartDec 2010
Primary CompletionJan 2011
TodayJul 2026
First PostedNov 29, 2010
Enrollment StartDec 1, 2010
Primary CompletionJan 10, 2011
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 15.6 years ago
Interventions
Cobimetinibdrug
Cobimetinib 20 mg will be given orally as tablet formulation in fasted or fed state, or as capsule formulation in fasted state.